Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Evaxion Biotech ( (EVAX) ) is now available.
On January 15, 2025, Evaxion Biotech announced the completion of dosing in a phase 2 trial for its personalized cancer vaccine, EVX-01, targeting advanced melanoma. This milestone suggests the trial is on schedule, with data expected in the latter half of 2025. Interim results showed a strong overall response rate, highlighting the potential of EVX-01 as a promising treatment, which could have significant commercial implications given the high incidence of melanoma. This advancement positions Evaxion strongly within the oncology sector, with potential benefits for stakeholders.
More about Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage TechBio company that specializes in developing vaccines powered by its AI-Immunology platform. The company focuses on creating personalized immunotherapies for cancer, bacterial diseases, and viral infections, leveraging artificial intelligence to understand and harness the human immune system.
YTD Price Performance: -10.66%
Average Trading Volume: 73,633
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.09M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.
